Patient‑derived orthotopic xenograft glioma models fail to replicate the magnetic resonance imaging features of the original patient tumor.
Aged
Animals
Brain Neoplasms
/ diagnostic imaging
Contrast Media
Diffusion Magnetic Resonance Imaging
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Glioma
/ diagnostic imaging
Humans
Magnetic Resonance Imaging
/ methods
Male
Mice
Mice, Nude
Mice, SCID
Middle Aged
Neoplasm Transplantation
Neoplastic Stem Cells
/ cytology
Primary Cell Culture
Sequence Analysis, RNA
Tumor Cells, Cultured
glioma
dynamic contrast-enhanced-magnetic resonance imaging
diffusion weighted imaging-magnetic resonance imaging
patient-derived xenograft
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
10
09
2019
accepted:
12
02
2020
pubmed:
24
4
2020
medline:
7
2
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
Patient‑derived orthotopic glioma xenograft models are important platforms used for pre‑clinical research of glioma. In the present study, the diagnostic ability of magnetic resonance imaging (MRI) was examined with regard to the identification of biomarkers obtained from patient‑derived glioma xenografts and human tumors. Conventional MRI, diffusion weighted imaging and dynamic contrast‑enhanced (DCE)‑MRI were used to analyze seven pairs of high grade gliomas with their corresponding xenografts obtained from non‑obese diabetic‑severe‑combined immunodeficiency nude mice. Tumor samples were collected for transcriptome sequencing and histopathological staining, and differentially expressed genes were screened between the original tumors and the corresponding xenografts. Gene Ontology (GO) analysis was performed to predict the functions of these genes. In 6 cases of xenografts with diffuse growth, the degree of enhancement was significantly lower compared with the original tumors. Histopathological staining indicated that the microvascular area and microvascular diameter of the xenografts were significantly lower compared with the original tumors (P=0.009 and P=0.007, respectively). In one case, there was evidence of nodular tumor growth in the mouse. Both MRI and histopathological staining showed a clear demarcation between the transplanted tumors and the normal brain tissues. The relative apparent diffusion coefficient values of the 7 cases examined were significantly higher compared with the corresponding original tumors (P=0.001) and transfer coefficient values derived from DCE‑MRI of the tumor area was significantly lower compared with the original tumors (P=0.016). GO analysis indicated that the expression levels of extracellular matrix‑associated genes, angiogenesis‑associated genes and immune function‑associated genes in the original tumors were higher compared with the corresponding xenografts. In conclusion, the data demonstrated that the MRI features of patient‑derived xenograft glioma models in mice were different compared with those of the original patient tumors. Differential gene expression may underlie the differences noted in the MRI features between original tumors and corresponding xenografts. The results of the present study highlight the precautions that should be taken when extrapolating data from patient‑derived xenograft studies, and their applicability to humans.
Identifiants
pubmed: 32323818
doi: 10.3892/or.2020.7538
pmc: PMC7107810
doi:
Substances chimiques
Contrast Media
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1619-1629Références
Front Oncol. 2018 Oct 10;8:429
pubmed: 30364119
Eur Radiol. 2019 Apr;29(4):1893-1902
pubmed: 30276676
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Cancer Med. 2018 Sep;7(9):4273-4283
pubmed: 30117304
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Sci Rep. 2017 Oct 24;7(1):13894
pubmed: 29066764
Cells. 2019 May 06;8(5):
pubmed: 31064068
NMR Biomed. 2013 Aug;26(8):1004-27
pubmed: 23674304
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Oral Oncol. 2014 Oct;50(10):963-70
pubmed: 25116700
Mol Imaging Biol. 2017 Feb;19(1):138-142
pubmed: 27357591
Neurosci Lett. 2010 Jul 12;478(3):165-70
pubmed: 20470863
J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9
pubmed: 27100354
Clin Cancer Res. 2007 Jun 15;13(12):3449-59
pubmed: 17575207
Contrast Media Mol Imaging. 2017 Mar 20;2017:7064120
pubmed: 29097933
Radiology. 2017 Aug;284(2):316-331
pubmed: 28723281
Cell Rep. 2013 Jan 31;3(1):260-73
pubmed: 23333277
Genes (Basel). 2018 Mar 12;9(3):
pubmed: 29534550
Neurol Res. 2003 Oct;25(7):729-38
pubmed: 14579791
Nat Commun. 2016 Apr 06;7:11185
pubmed: 27048880
Neuro Oncol. 2012 Feb;14(2):132-44
pubmed: 22067563
Clin Cancer Res. 2013 Sep 1;19(17):4816-23
pubmed: 23833308
Eur Radiol. 2017 Oct;27(10):4129-4144
pubmed: 28332014
PLoS One. 2014 Apr 11;9(4):e94045
pubmed: 24728236
Neuro Oncol. 2017 Jan;19(1):118-127
pubmed: 27502247
Eur Radiol. 2018 Sep;28(9):3819-3831
pubmed: 29619517
J Neurosurg. 2014 Aug;121(2):367-73
pubmed: 24949678
Cell Stem Cell. 2009 Jun 5;4(6):568-80
pubmed: 19497285
Gastric Cancer. 2015 Apr;18(2):306-13
pubmed: 24792410
J Neurooncol. 2015 Jan;121(2):373-80
pubmed: 25359396
J Immunol Res. 2017;2017:5813951
pubmed: 28512646
J Neurooncol. 2011 Sep;104(2):473-81
pubmed: 21240539
Magn Reson Med. 2014 May;71(5):1854-62
pubmed: 23798369
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Magn Reson Imaging. 2013 May;31(4):497-507
pubmed: 23228309
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Eur J Cancer. 2012 Mar;48(4):425-31
pubmed: 22226479
Nat Commun. 2017 Feb 10;8:14399
pubmed: 28186102
Q J Nucl Med Mol Imaging. 2018 Sep;62(3):239-253
pubmed: 29696946
Neuro Oncol. 2016 Oct;18(10):1367-78
pubmed: 27116978
Radiol Med. 2017 Nov;122(11):871-879
pubmed: 28689283
Magn Reson Imaging. 2017 Oct;42:114-122
pubmed: 28629955
J Pathol. 2016 Jul;239(3):355-64
pubmed: 27125842
Oncogene. 2008 Mar 27;27(14):2091-6
pubmed: 17934519
Brain Pathol. 2018 Jul;28(4):475-483
pubmed: 28481062
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Oncogene. 2017 Oct 26;36(43):6049-6058
pubmed: 28759044
Acta Neuropathol. 2017 Feb;133(2):263-282
pubmed: 28074274
Neuro Oncol. 2014 May;16(5):662-70
pubmed: 24353325
Neuro Oncol. 2015 Jun;17(6):784-800
pubmed: 25543124
Oncotarget. 2016 Oct 4;7(40):65888-65901
pubmed: 27589567